Patents by Inventor Eugene Pan

Eugene Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8255764
    Abstract: A decoder system comprises a tensor-product code (TPC) decoder that decodes a received data stream to generate a decoded signal. A mark module that replaces low-density parity check (LDPC) parity bits of the decoded signal with 0s to generate a reset output signal. A deinterleave module deinterleaves error correction parity bits that are within the reset output signal to generate a deinterleaved signal that comprises a decoded portion and a concatenated portion. The concatenated portion comprises the error correction parity bits. A parity decoder module removes the concatenated portion from the deinterleaved signal.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: August 28, 2012
    Assignee: Marvell International Ltd.
    Inventors: Engling Yeo, Eugene Pan, Henri Sutioso, Jun Xu, Shaohua Yang, Panu Chaichanavong, Gregory Burd, Zining Wu
  • Patent number: 8255765
    Abstract: A low-density parity check (LDPC) decoder comprises a decoded data stream generator that generates a decoded data stream based on a received data stream and a set of matrix-based codewords. The matrix-based codewords form a LDPC parity check matrix H. A decoder control module at least one of prewrites or replaces a selected portion of at least one of the plurality of codewords with zeros prior to generation of the decoded data stream.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: August 28, 2012
    Assignee: Marvell International Ltd.
    Inventors: Engling Yeo, Eugene Pan, Henri Sutioso, Jun Xu, Shaohua Yang, Panu Chaichanavong, Gregory Burd, Zining Wu
  • Patent number: 8156400
    Abstract: A decoder memory system comprises a first memory comprising at least a portion of a parity check matrix H. A second memory receives the portion from the first memory and that is associated with a previous decoding iteration. A third memory communicates with the first memory, receives the parity check matrix H and is associated with a current decoding iteration. A fourth memory comprises likelihood ratios. A control module generates a LDPC decoded signal based on the parity check matrix H, the previous decoded iteration and the likelihood ratios.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: April 10, 2012
    Assignee: Marvell International Ltd.
    Inventors: Engling Yeo, Eugene Pan, Henri Sutioso, Jun Xu, Shaohua Yang, Panu Chaichanavong, Gregory Burd, Zining Wu
  • Patent number: 8110187
    Abstract: The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: February 7, 2012
    Assignee: Hoffman-La Roche Inc.
    Inventors: Maurice Kent Gately, Ulrich Andreas Gubler, Jeffrey David Hulmes, Frank John Podlaski, Alvin Seth Stern, Richard Anthony Chizzonite, Yu-Ching Eugene Pan
  • Patent number: 8028216
    Abstract: An encoder system includes a receive module that receives a data stream. A parity generation module generates parity bits based on the data stream and a tensor-product code. A parity insertion module combines the parity bits and the data stream to generate encoded bits.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: September 27, 2011
    Assignee: Marvell International Ltd.
    Inventors: Engling Yeo, Eugene Pan, Henri Sutioso, Jun Xu, Shaohua Yang, Panu Chaichanavong, Gregory Burd, Zining Wu
  • Patent number: 6683046
    Abstract: The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 27, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maurice Kent Gately, Ulrich Andreas Gubler, Jeffrey David Hulmes, Frank John Podlaski, Alvin Seth Stern, Richard Anthony Chizzonite, Yu-Ching Eugene Pan
  • Publication number: 20030204059
    Abstract: The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth.
    Type: Application
    Filed: October 8, 2002
    Publication date: October 30, 2003
    Applicant: Hoffmann-LaRoche
    Inventors: Maurice Kent Gately, Ulrich Andreas Gubler, Jeffrey David Hulmes, Frank John Podlaski, Alvin Seth Stern, Richard Anthony Chizzonite, Yu-Ching Eugene Pan
  • Patent number: 5780597
    Abstract: The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 14, 1998
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maurice Kent Gately, Ulrich Andreas Gubler, Jeffrey David Hulmes, Frank John Podlaski, Alvin Seth Stern, Richard Anthony Chizzonite, Yu-Ching Eugene Pan